EpiCept is buying San Diego-based Maxim Pharmaceuticals for $136 million in stock. The deal will add Maxim's 55 workers and Ceplene, an experimental drug for acute myeloid leukemia and kidney cancer. Maxim is also collaborating with Schering-Plough on a drug for hepatitis C. EpiCept, which has operations in New Jersey and Germany, is expected to retain Maxim's San Diego research facility.
- read this article from New York Business for more